フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use Authorization...
Product batch announced in July yielded new regulatory stability data. These results will directly support...
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Communiqué de Presse Information...
Crossject announces its eligibility for France’s PEA-PME investment scheme Enables French retail investors to buy securities under preferential...
Crossject annonce son éligibilité au dispositif d’investissement PEA-PME Le PEA-PME permet aux investisseurs particuliers français d'acheter des...
Crossject reports financial results and business highlights for the first six months of 2024 Available cash €5.95 million, up from €2.3 million on...
Available cash €5.95 million, up from €2.3 million on December 31, 2023Reports stable investments in R&D...
Crossject présente ses résultats financiers et les faits marquants de ses activités pour le premier semestre 2024 Position de trésorerie : 5,95...
Crossject publiera ses résultats financiers du premier semestre et organisera un webcast le 23 Septembre 2024 Dijon, France, 17 septembre 2024...
Crossject to report first-half 2024 financial results and host webcast on September 23, 2024 Dijon, France, 17 September, 2024 - Crossject (ISIN:...
Crossject participera à la 26ème Annual Global Investment Conference de H.C. Wainwright, 9 au 11 septembre 2024 Communiqué de Presse Dijon...
Press Release Dijon, France August 22, 2024 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a...
Crossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024 Press Release Dijon, France August...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約